Skip to search formSkip to main contentSkip to account menu

CG200745

Known as: HDAC inhibitor CG200745 
A histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. CG200745 inhibits the catalytic activity of HDAC, resulting in an… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Renoprotective Effect of the Histone Deacetylase Inhibitor CG200745 in DOCA-Salt Hypertensive Rats
The novel histone deacetylase inhibitor CG200745 was initially developed to treat various hematological and solid cancers. We… 
2019
2019
Correction to: A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL
The blots of control and docetaxel for caspase-9, caspase-3, caspase-8, Bcl-XL, and tubulin in the Figure 4f were reused from… 
2019
2019
Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production
Obesity is growing rapidly worldwide due to consumption of westernized diet and lack of exercise. Obesity is one of the major… 
2018
2018
Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease
Tubulointerstitial fibrosis is a common feature of kidney disease. Histone deacetylase (HDAC) inhibitors have been reported to… 
2013
2013
Abstract 682: Synergistic effects of CG200745 combining with Gemcitabine and/or Erotinib in pancreatic cancer.
CG200745 is a HDAC inhibitor at the final stage of phase I clinical trial. In the current human studies with patient with… 
2012
2012
A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL
SummaryWe synthesized a novel hydroxamate-based pan-histone deacetylase inhibitor (HDACI), CG200745 {(E)-2-(Naphthalen-1… 
2012
2012
Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells
SummaryHistone deacetylase (HDAC) plays an important role in cancer onset and progression. Therefore, inhibition of HDAC offers… 
2012
2012
Abstract 4666: Anti-leukemic activity of a novel histone deacetylase inhibitor, CG200745, via induction of mitochondrial dysfunction in acute myeloid leukemia
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: Acute myeloid leukemia (AML) can be… 
2009
2009
Abstract #4561: Preclinical studies of CG200745, novel histone deacetylase inhibitor discovered using structure-based drug discovery technologies
Histone acetylation and deacetylation play essential roles in modifying chromatin structure and regulating gene expression in… 
2008
2008
DMPK and early tox study of a novel HDAC inhibiotr, CG200745
2617 Histone deacetylases (HDAC) which catalyse the deacetylation of histones are emerging as an important cancer target… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)